In the latest step to combat the epidemic of opioid abuse, U.S. officials urge generic drug makers to make changes to opioids.
Mainly supportive of guidelines, but concerns include a lack of evidence underlying some new recommendations.
A pharmacist-led comprehensive medication assessment showed a high prevalence of polypharmacy and inappropriate medication use among older patients with cancer.
Children in remission from acute lymphocytic leukemia (ALL) must take 6-mercaptopurine (6MP) for 2 years to prevent disease reemergence; however, a study shows that an estimated 25% of children in remission are not taking this essential maintenance medication at least 90% of the time, tripling their relapse risk.
Prescribers of extended-release/long-acting opioid analgesics are encouraged to participate in continuing medical education provided by manufacturers of these analgesics.
Falsified and substandard medications pose public health problems around the world, and international action should be taken to combat the phenomenon.
To assist industry in developing new formulations of opioid drugs with abuse-deterrent properties.
One-third of outpatients with breast, prostate, colon/rectum, or lung cancer were receiving insufficient pain treatment, particularly minorities.
Nurses working in hospitals with basic electronic health records report fewer problems with patient safety and quality-related outcomes.
A survey completed by approximately 400 oncology nurses practicing in ambulatory settings indicated that 16.9% had had their skin or eyes exposed to the toxic drugs they deliver.
Palliative care interventions should be introduced at diagnosis as a part of disease management rather than not until the end of life, suggests a review of cancer pain management.
A method employing fluorescent detection appears to be more adept than conventional immunohistochemistry in identifying estrogen receptor (ER)-positive breast cancers.
Disruptions in supply impact patient care. Nurses should know when to use a substitution drug and when to wait for the next shipment.
Roxane Laboratories has made labeling and product-packaging changes to its morphine sulfate oral solution 100 mg per 5 mL (20 mg/mL) due to accidental overdoses that resulted in adverse events and deaths.
A tablet delivering transmucosal fentanyl, Abstral is indicated for the management of breakthrough pain in adult cancer patients who are already using opioids around the clock.
The advisor forum answers questions about drug screens, coping with chemo brain, anemia in patients with MDS, and more.
This article reviews current practices of opioid prescribing in palliative care and suggests some pointers for safe prescribing for these patients.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
- Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|